

Shibo Jiang

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1573234/shibo-jiang-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

485
papers

25,763
citations

80
h-index

141
g-index

520
ext. papers

30,788
ext. citations

8.8
avg, IF

7.71
L-index

#	Paper	IF	Citations
485	The spike protein of SARS-CoV--a target for vaccine and therapeutic development. <i>Nature Reviews Microbiology</i> , 2009 , 7, 226-36	22.2	1007
484	Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. <i>Cellular and Molecular Immunology</i> , 2020 , 17, 613-620	15.4	910
483	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. <i>Emerging Microbes and Infections</i> , 2020 , 9, 382-385	18.9	862
482	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. <i>Cell Research</i> , 2020 , 30, 343-355	24.7	745
481	Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. <i>Journal of Pathology</i> , 2004 , 203, 622-30	9.4	722
480	Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. <i>Trends in Immunology</i> , 2020 , 41, 355-359	14.4	476
479	Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. <i>Science</i> , 2020 , 369, 1603-1607	33.3	434
478	HIV-1 inhibition by a peptide. <i>Nature</i> , 1993 , 365, 113	50.4	425
477	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. <i>Cellular and Molecular Immunology</i> , 2020 , 17, 765-767	15.4	382
476	Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. <i>Lancet, The</i> , 2004 , 363, 938-47	40	380
475	Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 324, 773-81	3.4	316
474	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	282	
473	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. <i>Science Advances</i> , 2019 , 5, eaav4580	14.3	268
472	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. <i>Nature Communications</i> , 2014 , 5, 3067	17.4	247
471	Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 12123-8	11.5	246
470	Recent advances in the detection of respiratory virus infection in humans. <i>Journal of Medical Virology</i> , 2020 , 92, 408-417	19.7	233
469	N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 4349-59	5.9	224

468	Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. <i>Microbes and Infection</i> , 2020 , 22, 74-79	9.3	220
467	A distinct name is needed for the new coronavirus. <i>Lancet, The</i> , 2020 , 395, 949	4.0	216
466	An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. <i>Emerging Microbes and Infections</i> , 2020 , 9, 275-277	18.9	210
465	Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. <i>Cell</i> , 2007 , 129, 263-75	56.2	206
464	Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. <i>Journal of Immunology</i> , 2005 , 174, 4908-15	5.3	202
463	Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. <i>Frontiers in Microbiology</i> , 2020 , 11, 298	5.7	188
462	Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. <i>Journal of Biological Chemistry</i> , 2005 , 280, 11259-73	5.4	183
461	Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. <i>Journal of Virology</i> , 2014 , 88, 7796-805	6.6	182
460	Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 12516-21	11.5	182
459	Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. <i>Virology</i> , 2005 , 339, 213-25	3.6	178
458	Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry. <i>Viruses</i> , 2015 , 8,	6.2	178
457	MERS-CoV spike protein: a key target for antivirals. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 131-143	4.3	176
456	The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 92	21	170
455	Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. <i>Journal of Biological Chemistry</i> , 2008 , 283, 11126-34	5.4	169
454	AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. <i>Cell Research</i> , 2021 , 31, 126-140	24.7	165
453	Identification of Human Single-Domain Antibodies against SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020 , 27, 891-898.e5	23.4	155
452	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. <i>JAMA Internal Medicine</i> , 2020 , 180, 1356-1362	11.5	152
451	SARS Vaccine Development. <i>Emerging Infectious Diseases</i> , 2005 , 11, 1016-1020	10.2	149

450	Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 3203-9	8.3	147
449	Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. <i>Angewandte Chemie - International Edition</i> , 2002 , 41, 278-81	16.4	146
448	Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. <i>Journal of Virology</i> , 2013 , 87, 9939-42	6.6	140
447	Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. <i>Emerging Microbes and Infections</i> , 2018 , 7, 77	18.9	136
446	Receptor usage and cell entry of porcine epidemic diarrhea coronavirus. <i>Journal of Virology</i> , 2015 , 89, 6121-5	6.6	129
445	Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. <i>Vaccine</i> , 2007 , 25, 2832-8	4.1	128
444	Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. <i>Journal of Immunology</i> , 2004 , 173, 4050-7	5.3	128
443	A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. <i>PLoS ONE</i> , 2013 , 8, e81587	3.7	126
442	SARS vaccine development. <i>Emerging Infectious Diseases</i> , 2005 , 11, 1016-20	10.2	126
441	HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. <i>Current Pharmaceutical Design</i> , 2007 , 13, 143-62	3.3	123
440	Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 16332-7	11.5	118
439	Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2005 , 1723, 270-81	4	117
438	HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. <i>Journal of Biological Chemistry</i> , 2007 , 282, 9612-9620	5.4	115
437	Current advancements and potential strategies in the development of MERS-CoV vaccines. <i>Expert Review of Vaccines</i> , 2014 , 13, 761-74	5.2	113
436	A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. <i>Journal of Virology</i> , 2014 , 88, 7045-53	6.6	112
435	Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. <i>Journal of Biological Chemistry</i> , 2006 , 281, 18787-92	5.4	109
434	Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 325, 445-52	3.4	109
433	Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. <i>Vaccine</i> , 2014 , 32, 2100-8	4.1	107

432	Peptide and non-peptide HIV fusion inhibitors. <i>Current Pharmaceutical Design</i> , 2002 , 8, 563-80	3.3	107
431	Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. <i>Science</i> , 2020 , 367,	33.3	105
430	Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design. <i>Vaccine</i> , 2014 , 32, 6170-6176	4.1	102
429	A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. <i>Virology Journal</i> , 2013 , 10, 266	6.1	102
428	Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. <i>Journal of Immunology</i> , 2008 , 180, 948-56	5.3	102
427	Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 7843-54	8.3	99
426	A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. <i>Journal of Virological Methods</i> , 1999 , 80, 85-96	2.6	99
425	Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. <i>Virology</i> , 2005 , 334, 74-82	3.6	97
424	Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. <i>Cellular and Molecular Immunology</i> , 2016 , 13, 180-90	15.4	96
423	Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus. <i>Journal of Virology</i> , 2015 , 89, 9119-23	6.6	96
422	Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 359, 174-9	3.4	96
421	Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. <i>Expert Review of Vaccines</i> , 2012 , 11, 1405-13	5.2	93
420	Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. <i>Virology</i> , 2009 , 393, 144-50	3.6	93
419	Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. <i>Journal of Immunology</i> , 2006 , 176, 6085-92	5.3	93
418	Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. <i>Journal of Virology</i> , 2006 , 80, 5757-67	6.6	92
417	A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. <i>Cellular and Molecular Immunology</i> , 2020 , 17, 554	15.4	91
416	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 27141-27147	11.5	91
415	Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. <i>Nature Communications</i> , 2015 , 6, 8223	17.4	90

414	Research and development of universal influenza vaccines. <i>Microbes and Infection</i> , 2010 , 12, 280-6	9.3	88
413	Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidene)methyl)furans as HIV-1 entry inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 7631-9	8.3	86
412	Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. <i>Journal of Virology</i> , 2004 , 78, 2627-31	6.6	84
411	Prospects for a MERS-CoV spike vaccine. <i>Expert Review of Vaccines</i> , 2018 , 17, 677-686	5.2	83
410	A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. <i>Nature Communications</i> , 2017 , 8, 15672	17.4	83
409	Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. <i>Human Vaccines and Immunotherapeutics</i> , 2014 , 10, 648-58	4.4	82
408	Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. <i>Virus Research</i> , 2014 , 194, 200-10	6.4	79
407	Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. <i>Nature Communications</i> , 2016 , 7, 13473	17.4	77
406	A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. <i>Virology</i> , 2016 , 499, 375-382	3.6	76
405	Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus. <i>PLoS ONE</i> , 2010 , 5, e9549	3.7	76
404	Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. <i>ChemMedChem</i> , 2010 , 5, 1813-24	3.7	76
403	Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. <i>Journal of Virology</i> , 2008 , 82, 6349-58	6.6	76
402	Learning from the past: development of safe and effective COVID-19 vaccines. <i>Nature Reviews Microbiology</i> , 2021 , 19, 211-219	22.2	75
401	A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. <i>Cell Research</i> , 2020 , 30, 932-935	24.7	73
400	An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. <i>Virology Journal</i> , 2010 , 7, 9	6.1	72
399	Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1. <i>Journal of Medicinal Chemistry</i> , 1994 , 37, 1099-108	8.3	72
398	Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. <i>Journal of Infectious Diseases</i> , 2015 , 212, 1894-903	7.03	71
397	Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. <i>Antiviral Research</i> , 2020 , 179, 104820	10.8	71

396	Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013 , 49, 221-30	5.7	71
395	Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. <i>Journal of Biological Chemistry</i> , 2007 , 282, 25631-9	5.4	71
394	Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. <i>Biochemistry</i> , 2000 , 39, 1634-42	3.2	71
393	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 282	21	71
392	Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. <i>Nature Medicine</i> , 1996 , 2, 230-4	50.5	69
391	Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. <i>Viruses</i> , 2019 , 11,	6.2	69
390	A method to identify trace sulfated IgG N-glycans as biomarkers for rheumatoid arthritis. <i>Nature Communications</i> , 2017 , 8, 631	17.4	67
389	Genomic signature and protein sequence analysis of a novel influenza A(H7N9) virus that causes an outbreak in humans in China. <i>Microbes and Infection</i> , 2013 , 15, 432-9	9.3	67
388	Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. <i>Vaccine</i> , 2008 , 26, 1644-51	4.1	67
387	Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 3718-26	9.7	67
386	Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. <i>Journal of Virology</i> , 2016 , 90, 57-67	6.6	64
385	Vaccines for the prevention against the threat of MERS-CoV. <i>Expert Review of Vaccines</i> , 2016 , 15, 1123-34	3.2	64
384	Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 572-9	8.3	63
383	Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors. <i>Peptides</i> , 2003 , 24, 1303-13	3.8	63
382	A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. <i>Journal of Virology</i> , 2018 , 92,	6.6	62
381	Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 3039-48	3.4	61
380	Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 1244-50	4.4	60
379	Modulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1 α <i>Nucleic Acids Research</i> , 2014 , 42, 6578-90	20.1	60

378	Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 1830-6	5.9	60
377	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 233	21	60
376	Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. <i>Microbes and Infection</i> , 2013 , 15, 625-9	9.3	59
375	Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 1393-401	5.9	59
374	Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. <i>PLoS ONE</i> , 2015 , 10, e0145561	3.7	59
373	Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 212	21	59
372	Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. <i>Journal of Virology</i> , 2017 , 91,	6.6	58
371	Single-Domain Antibodies As Therapeutics against Human Viral Diseases. <i>Frontiers in Immunology</i> , 2017 , 8, 1802	8.4	58
370	Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34. <i>ChemBioChem</i> , 2005 , 6, 1068-74	3.8	58
369	Hepatitis B virus DNA in sera of virus carriers positive exclusively for antibodies to the hepatitis B core antigen. <i>Journal of Medical Virology</i> , 1991 , 35, 55-9	19.7	58
368	Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. <i>Journal of Virology</i> , 2008 , 82, 11129-39	6.6	57
367	Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. <i>Cellular and Molecular Immunology</i> , 2020 , 17, 894	15.4	56
366	A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 270, 153-7	3.4	54
365	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. <i>Cell Reports</i> , 2021 , 34, 108699	10.6	54
364	In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 795-805	4.4	53
363	Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides. <i>Science Translational Medicine</i> , 2014 , 6, 262ra157	17.5	53
362	Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. <i>BMC Infectious Diseases</i> , 2002 , 2, 6	4	53
361	Neutralizing antibodies for the treatment of COVID-19. <i>Nature Biomedical Engineering</i> , 2020 , 4, 1134-1139		52

360	Respiratory syncytial virus entry inhibitors targeting the F protein. <i>Viruses</i> , 2013 , 5, 211-25	6.2	52
359	Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. <i>Virology Journal</i> , 2010 , 7, 299	6.1	52
358	Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. <i>Biochemistry</i> , 2003 , 42, 14150-8	3.2	52
357	CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entry. <i>European Journal of Pharmacology</i> , 2011 , 660, 460-7	5.3	51
356	HIV-1 gp41 fusion intermediate: a target for HIV therapeutics. <i>Journal of the Formosan Medical Association</i> , 2010 , 109, 94-105	3.2	50
355	Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 5309-14	9.7	50
354	Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. <i>Vaccine</i> , 2020 , 38, 7533-7541	4.1	50
353	Receptor-binding domain-based subunit vaccines against MERS-CoV. <i>Virus Research</i> , 2015 , 202, 151-9	6.4	49
352	A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. <i>Retrovirology</i> , 2012 , 9, 104	3.6	49
351	Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 269, 641-6	3.4	49
350	Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41. <i>Current Topics in Medicinal Chemistry</i> , 2016 , 16, 1074-90	3	49
349	Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. <i>Clinical Infectious Diseases</i> , 2015 , 60, 586-95	11.6	48
348	Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway. <i>Cancer Letters</i> , 2015 , 364, 79-88	9.9	48
347	ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 4987-98	5.9	48
346	Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41. <i>Journal of Biomolecular Screening</i> , 2003 , 8, 685-93		47
345	Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients. <i>Biologicals</i> , 1999 , 27, 11-21	1.8	47
344	Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	46
343	Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. <i>Vaccine</i> , 2006 , 24, 5498-508	4.1	46

342	Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains. <i>Journal of Virology</i> , 2009 , 83, 7862-72	6.6	45
341	The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 298, 552-8	3.4	45
340	High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. <i>Current Pharmaceutical Design</i> , 2004 , 10, 1827-43	3.3	45
339	Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. <i>Vaccine</i> , 2018 , 36, 1853-1862	4.1	44
338	Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. <i>Journal of Biological Chemistry</i> , 2008 , 283, 30376-84	5.4	44
337	Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. <i>Human Vaccines and Immunotherapeutics</i> , 2017 , 13, 1615-1624	4.4	43
336	Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. <i>Journal of Biological Chemistry</i> , 2010 , 285, 25506-15	5.4	43
335	Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. <i>Scientific Reports</i> , 2016 , 6, 31629	4.9	42
334	The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus. <i>Virologica Sinica</i> , 2020 , 35, 263-265	6.4	41
333	Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 8287-97	8.3	41
332	Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. <i>Biochemical and Biophysical Research Communications</i> , 2009 , 384, 486-90	3.4	41
331	In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. <i>Journal of Biological Chemistry</i> , 2011 , 286, 3277-87	5.4	41
330	Receptor-binding domain as a target for developing SARS vaccines. <i>Journal of Thoracic Disease</i> , 2013 , 5 Suppl 2, S142-8	2.6	41
329	Visual and Motor Deficits in Grown-up Mice with Congenital Zika Virus Infection. <i>EBioMedicine</i> , 2017 , 20, 193-201	8.8	40
328	A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. <i>Viral Immunology</i> , 2010 , 23, 211-9	1.7	40
327	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. <i>Nature Communications</i> , 2021 , 12, 866	17.4	40
326	A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection. <i>Fluoterap</i> 2012 , 83, 348-55	3.2	39
325	Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket. <i>Viruses</i> , 2013 , 5, 127-49	6.2	39

324	Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. <i>Journal of Biological Chemistry</i> , 2007 , 282, 6143-52	5.4	39
323	Design, synthesis and biological evaluation of 3-substituted 2,5-dimethyl-N-(3-(1H-tetrazol-5-yl)phenyl)pyrroles as novel potential HIV-1 gp41 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 6726-34	3.4	38
322	Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 4906-16	8.3	38
321	Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. <i>Journal of Virology</i> , 2008 , 82, 6869-79	6.6	38
320	Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. <i>Virology</i> , 2006 , 353, 6-16	3.6	38
319	XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. <i>AIDS Research and Human Retroviruses</i> , 2002 , 18, 989-97	1.6	38
318	Association of candidate susceptible loci with chronic infection with hepatitis B virus in a Chinese population. <i>Journal of Medical Virology</i> , 2010 , 82, 371-8	19.7	37
317	Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. <i>Journal of Biological Chemistry</i> , 2008 , 283, 16723-31	5.4	37
316	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. <i>Cell Host and Microbe</i> , 2017 , 22, 471-483.e5	23.4	36
315	Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010 , 20, 189-92	2.9	36
314	Development of Small-Molecule MERS-CoV Inhibitors. <i>Viruses</i> , 2018 , 10,	6.2	36
313	A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. <i>Viruses</i> , 2018 , 10,	6.2	35
312	Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection. <i>Cell Research</i> , 2021 , 31, 98-100	24.7	35
311	Development of therapeutics for treatment of Ebola virus infection. <i>Microbes and Infection</i> , 2015 , 17, 109-17	9.3	34
310	Current development of COVID-19 diagnostics, vaccines and therapeutics. <i>Microbes and Infection</i> , 2020 , 22, 231-235	9.3	34
309	A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. <i>Journal of Infection</i> , 2013 , 66, 464-6	18.9	34
308	Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. <i>Aids</i> , 2009 , 23, 639-41	3.5	34
307	Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2007 , 46, 198-205	13.4	34

306	Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 742-4	5.9	33
305	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. <i>Emerging Microbes and Infections</i> , 2017 , 6, e89	18.9	33
304	Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. <i>Emerging Microbes and Infections</i> , 2012 , 1, e13	18.9	33
303	Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation. <i>ACS Combinatorial Science</i> , 2006 , 8, 531-9		33
302	Design, synthesis, and biological evaluation of 1-[(2-benzyloxy/alkoxy)methyl]-5-halo-6-arylluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 2242-50	8.3	32
301	Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. <i>Journal of Immunological Methods</i> , 2006 , 317, 21-30	2.5	32
300	Vaccine design for severe acute respiratory syndrome coronavirus. <i>Viral Immunology</i> , 2005 , 18, 327-32	1.7	32
299	Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs <i>Prunella vulgaris</i> and <i>Rhizoma cibotte</i> . <i>Life Sciences</i> , 2002 , 71, 1779-91	6.8	32
298	N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes. <i>Clinical Immunology</i> , 2000 , 96, 236-42	9	32
297	A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. <i>PLoS ONE</i> , 2011 , 6, e16555	3.7	31
296	Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth <i>Onchocerca volvulus</i> , can directly bind and activate antigen-presenting cells. <i>Journal of Immunology</i> , 2009 , 182, 4005-16	5.3	31
295	Complement inhibition alleviates paraquat-induced acute lung injury. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011 , 45, 834-42	5.7	31
294	HIV-1-co-receptors binding. <i>Nature Medicine</i> , 1997 , 3, 367-8	50.5	31
293	Advancements in the development of subunit influenza vaccines. <i>Microbes and Infection</i> , 2015 , 17, 123-34	3.3	30
292	Discovery of Hydrocarbon-Stapled Short β -Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 2018-2026	8.3	30
291	Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses. <i>Emerging Microbes and Infections</i> , 2018 , 7, 7	18.9	30
290	Polyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infection. <i>PLoS ONE</i> , 2013 , 8, e59777	3.7	30
289	HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. <i>PLoS ONE</i> , 2011 , 6, e18233	3.7	30

288	An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. <i>Virology Journal</i> , 2010 , 7, 151	6.1	30
287	A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action. <i>Reviews in Medical Virology</i> , 2016 , 26, 242-50	11.7	30
286	Cell Entry of Porcine Epidemic Diarrhea Coronavirus Is Activated by Lysosomal Proteases. <i>Journal of Biological Chemistry</i> , 2016 , 291, 24779-24786	5.4	29
285	Immunogenicity and antigenic relationships among spike proteins of porcine epidemic diarrhea virus subtypes G1 and G2. <i>Archives of Virology</i> , 2016 , 161, 537-47	2.6	29
284	Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 7342-54	8.3	29
283	An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2533-44	5.1	29
282	Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. <i>Journal of Molecular Recognition</i> , 1995 , 8, 304-16	2.6	29
281	From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development. <i>Microbes and Infection</i> , 2020 , 22, 245-253	9.3	28
280	Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza. <i>Nature Communications</i> , 2018 , 9, 2358	17.4	28
279	Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin. <i>Journal of Virology</i> , 2013 , 87, 2215-25	6.6	28
278	Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. <i>Microbes and Infection</i> , 2015 , 17, 142-8	9.3	28
277	Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 397, 580-5	3.4	28
276	Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. <i>Vaccine</i> , 2010 , 28, 7233-40	4.1	28
275	Salmonella typhi Ty21a bacterial ghost vector augments HIV-1 gp140 DNA vaccine-induced peripheral and mucosal antibody responses via TLR4 pathway. <i>Vaccine</i> , 2012 , 30, 5733-9	4.1	27
274	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 3593-608	8.3	27
273	Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang Province of China. <i>Retrovirology</i> , 2009 , 6, 45	3.6	27
272	3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1700-11	5.9	27
271	De Novo Design of α -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 8734-8745	8.3	27

270	Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice. <i>Scientific Reports</i> , 2017 , 7, 43373	4.9	26
269	The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. <i>Protein and Cell</i> , 2018 , 9, 596-615	7.2	26
268	Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors. <i>Viruses</i> , 2019 , 11,	6.2	26
267	HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2012 , 1818, 2950-7	3.8	26
266	Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1. <i>PLoS ONE</i> , 2012 , 7, e37381	3.7	26
265	rOv-ASP-1, a recombinant secreted protein of the helminth <i>Onchocercavolvulus</i> , is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens. <i>Vaccine</i> , 2005 , 23, 3446-52	4.1	26
264	The adjuvanticity of an <i>O. volvulus</i> -derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. <i>PLoS ONE</i> , 2012 , 7, e37019	3.7	26
263	Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 3689-704	8.3	26
262	Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. <i>Scientific Reports</i> , 2015 , 5, 13028	4.9	25
261	Studying the nucleated mammalian cell membrane by single molecule approaches. <i>PLoS ONE</i> , 2014 , 9, e91595	3.7	25
260	Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 6895-8	2.9	25
259	A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 344, 106-13	3.4	25
258	A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity. <i>Aids</i> , 2017 , 31, 885-894	3.5	24
257	A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. <i>PLoS ONE</i> , 2013 , 8, e53568	3.7	24
256	Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009 , 19, 5482-5	2.9	24
255	Microbicides: stopping HIV at the gate. <i>Lancet, The</i> , 2006 , 368, 431-3	4.0	24
254	Antivirals with common targets against highly pathogenic viruses. <i>Cell</i> , 2021 , 184, 1604-1620	56.2	24
253	Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. <i>Nature Communications</i> , 2021 , 12, 1517	17.4	24

252	Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy. <i>Aids</i> , 2016 , 30, 827-38	3.5	24
251	Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	23
250	Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. <i>Science China Life Sciences</i> , 2017 , 60, 1399-1402	8.5	23
249	Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. <i>Journal of Virology</i> , 2017 , 91,	6.6	23
248	Advancements in Developing Strategies for Sterilizing and Functional HIV Cures. <i>BioMed Research International</i> , 2017 , 2017, 6096134	3	23
247	Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles ₃ and related derivatives targeting HIV-1 gp41. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 7539-48		
246	Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors. <i>PLoS ONE</i> , 2011 , 6, e17605	3.7	23
245	Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement 2020 ,		23
244	Development of Small-Molecule Inhibitors Against Zika Virus Infection. <i>Frontiers in Microbiology</i> , 2019 , 10, 2725	5.7	23
243	Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014). <i>Expert Opinion on Therapeutic Patents</i> , 2015 , 25, 159-73	6.8	22
242	ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2014 , 1838, 1296-305	3.8	22
241	Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 67, 1-6	3.1	22
240	Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins. <i>AIDS Research and Human Retroviruses</i> , 1991 , 7, 813-23	1.6	22
239	An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. <i>Emerging Microbes and Infections</i> , 2016 , 5, e65	18.9	22
238	Metformin combined with nelfinavir induces SIRT3/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice. <i>European Journal of Pharmacology</i> , 2019 , 848, 62-69	5.3	21
237	A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 398, 506-12	3.4	21
236	Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. <i>Journal of Virology</i> , 2012 , 86, 589-93	6.6	21
235	Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines. <i>Protein and Cell</i> , 2010 , 1, 342-354	7.2	21

234	Plasma membrane-associated proteins with the ability to partially inhibit perforin-mediated lysis. <i>Immunology Letters</i> , 1991 , 28, 101-8	4.1	21
233	Development of subunit vaccines against severe acute respiratory syndrome. <i>Drugs of Today</i> , 2008 , 44, 63-73	2.5	21
232	Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 220	21	21
231	Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. <i>Viruses</i> , 2019 , 11,	6.2	20
230	Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 2527-39	8.3	20
229	HIV-associated dementia in the era of highly active antiretroviral therapy (HAART). <i>Microbes and Infection</i> , 2011 , 13, 419-25	9.3	20
228	Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. <i>Retrovirology</i> , 2010 , 7, 37	3.6	20
227	Rapid adaptation of SARS-CoV-2 in BALB/c mice: Novel mouse model for vaccine efficacy		20
226	Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. <i>Viruses</i> , 2019 , 11,	6.2	20
225	Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2017 , 27, 707-719	6.8	19
224	Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells. <i>Frontiers in Microbiology</i> , 2020 , 11, 1063	5.7	19
223	HIV-1 impairs human retinal pigment epithelial barrier function: possible association with the pathogenesis of HIV-associated retinopathy. <i>Laboratory Investigation</i> , 2014 , 94, 777-87	5.9	19
222	Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. <i>MAbs</i> , 2010 , 2, 266-74	6.6	19
221	Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK). <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 7689-96	8.3	19
220	Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2004 , 12, 1215-20	5.4	19
219	Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis		19
218	Cytoplasts from cytotoxic T lymphocytes are resistant to perforin-mediated lysis. <i>Molecular Immunology</i> , 1991 , 28, 1011-8	4.3	18
217	The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. <i>Frontiers in Microbiology</i> , 2018 , 9, 2643	5.7	18

216	HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. <i>Emerging Microbes and Infections</i> , 2017 , 6, e59	18.9	17
215	Peptides derived from HIV-1 gp120 co-receptor binding domain form amyloid fibrils and enhance HIV-1 infection. <i>FEBS Letters</i> , 2014 , 588, 1515-22	3.8	17
214	Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 3284-6	2.9	17
213	PA-356R is a unique signature of the avian influenza A (H7N9) viruses with bird-to-human transmissibility: potential implication for animal surveillances. <i>Journal of Infection</i> , 2013 , 67, 490-4	18.9	17
212	HIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected]. <i>PLoS ONE</i> , 2013 , 8, e54452	3.7	17
211	The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion. <i>FASEB Journal</i> , 2008 , 22, 1179-92	0.9	17
210	Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. <i>Virologica Sinica</i> , 2020 , 35, 857-860	6.4	17
209	The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 132	21	17
208	Characterization by high-resolution crystal structure analysis of a triple-helix region of human collagen type III with potent cell adhesion activity. <i>Biochemical and Biophysical Research Communications</i> , 2019 , 508, 1018-1023	3.4	17
207	Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. <i>MAbs</i> , 2016 , 8, 761-74	6.6	16
206	In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires. <i>Frontiers in Immunology</i> , 2018 , 9, 128	8.4	16
205	Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses. <i>Frontiers of Medicine</i> , 2017 , 11, 449-461	12	16
204	Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. <i>Journal of Infection</i> , 2013 , 67, 348-50	18.9	16
203	Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor. <i>Journal of Virology</i> , 2010 , 84, 9359-68	6.6	16
202	Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors. <i>Immunobiology</i> , 2009 , 214, 51-60	3.4	16
201	Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity. <i>European Journal of Pharmacology</i> , 2007 , 565, 54-9	5.3	16
200	The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation. <i>Biochemical Journal</i> , 2007 , 403, 565-71	3.8	16
199	Identification of the HIV-1 gp41 core-binding motif--HXXNPF. <i>FEBS Letters</i> , 2006 , 580, 4807-14	3.8	16

198	Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): application for rapid screening of HIV-1 fusion inhibitors. <i>Journal of Virological Methods</i> , 2003 , 107, 155-61	2.6	16
197	A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 71	21	16
196	Long-term Survival of SARS-CoV-2 on Salmon as a Source for International Transmission. <i>Journal of Infectious Diseases</i> , 2021 , 223, 537-539	7	16
195	Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	15
194	Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy. <i>Journal of Virology</i> , 2015 , 89, 6960-4	6.6	15
193	ADS-J1 inhibits semen-derived amyloid fibril formation and blocks fibril-mediated enhancement of HIV-1 infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5123-34	5.9	15
192	Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection. <i>Microbes and Infection</i> , 2013 , 15, 506-10	9.3	15
191	Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination. <i>FASEB Journal</i> , 2012 , 26, 1018-26	0.9	15
190	The lymphocyte pore-forming protein perforin is associated with granules by a pH-dependent mechanism. <i>Immunology Letters</i> , 1989 , 22, 23-7	4.1	15
189	Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies.. <i>Emerging Microbes and Infections</i> , 2022 , 1-18	18.9	15
188	Differences in the pathogenicity and inflammatory responses induced by avian influenza A/H7N9 virus infection in BALB/c and C57BL/6 mouse models. <i>PLoS ONE</i> , 2014 , 9, e92987	3.7	15
187	A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. <i>Molecules</i> , 2019 , 24,	4.8	14
186	Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application. <i>Critical Care Medicine</i> , 2018 , 46, e419-e425	1.4	14
185	Design of highly potent HIV fusion inhibitors based on artificial peptide sequences. <i>Chemical Communications</i> , 2012 , 48, 11579-81	5.8	14
184	Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1498-508	1.6	14
183	Serological investigation of subclinical influenza A(H7H9) infection among healthcare and non-healthcare workers in Zhejiang Province, China. <i>Clinical Infectious Diseases</i> , 2013 , 57, 919-21	11.6	14
182	Identification of HBsAg-specific antibodies from a mammalian cell displayed full-length human antibody library of healthy immunized donor. <i>Cellular and Molecular Immunology</i> , 2012 , 9, 184-90	15.4	14
181	A nanoparticle-encapsulated non-nucleoside reverse-transcriptase inhibitor with enhanced anti-HIV-1 activity and prolonged circulation time in plasma. <i>Current Pharmaceutical Design</i> , 2015 , 21, 925-35	3.3	14

180	Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD. <i>Viruses</i> , 2019 , 11,	6.2	14
179	Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. <i>Microbes and Infection</i> , 2018 , 20, 626-634	9.3	14
178	Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. <i>Protein and Cell</i> , 2021 , 12, 84-88	7.2	14
177	Development of oncolytic virotherapy: from genetic modification to combination therapy. <i>Frontiers of Medicine</i> , 2020 , 14, 160-184	12	13
176	Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China. <i>Virology Journal</i> , 2013 , 10, 10	6.1	13
175	Development of a heat-stable and orally delivered recombinant M2e-expressing <i>B. subtilis</i> spore-based influenza vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2014 , 10, 3649-58	4.4	13
174	Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity. <i>Aids</i> , 2014 , 28, 1251-60	3.5	13
173	A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability. <i>Journal of Biological Chemistry</i> , 2011 , 286, 28425-34	5.4	13
172	Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 947-55	1.6	13
171	A herpesvirus inhibitor from bovine whey. <i>Lancet, The</i> , 1996 , 347, 1703-1704	4.0	13
170	Chemically modified bovine beta-lactoglobulin blocks uptake of HIV-1 by colon- and cervix-derived epithelial cell lines. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996 , 13, 461-2		13
169	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 288	21	13
168	N-Substituted Pyrrole Derivative 12m Inhibits HIV-1 Entry by Targeting Gp41 of HIV-1 Envelope Glycoprotein. <i>Frontiers in Pharmacology</i> , 2019 , 10, 859	5.6	12
167	Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1537-45	5.1	12
166	Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection. <i>Microbes and Infection</i> , 2017 , 19, 641-647	9.3	12
165	A novel strategy for rapid construction of libraries of full-length antibodies highly expressed on mammalian cell surfaces. <i>Acta Biochimica Et Biophysica Sinica</i> , 2010 , 42, 575-84	2.8	12
164	Evaluation of recombinant <i>Onchocerca volvulus</i> activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines. <i>Vaccine</i> , 2008 , 26, 5022-9	4.1	12
163	Interaction of HIV-1 gp41 core with NPF motif in Epsin: implication in endocytosis of HIV. <i>Journal of Biological Chemistry</i> , 2008 , 283, 14994-5002	5.4	12

162	HIV-1 gp41 ectodomain enhances <i>Cryptococcus neoformans</i> binding to HBMEC. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 356, 899-905	3.4	12
161	Differential susceptibility of type III erythrocytes of paroxysmal nocturnal hemoglobinuria to lysis mediated by complement and perforin. <i>Biochemical and Biophysical Research Communications</i> , 1989 , 162, 316-25	3.4	12
160	Real-time imaging of individual virion-triggered cortical actin dynamics for human immunodeficiency virus entry into resting CD4 T cells. <i>Nanoscale</i> , 2020 , 12, 115-129	7.7	12
159	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. <i>Acta Pharmaceutica Sinica B</i> , 2021 ,	15.5	12
158	Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. <i>Aids</i> , 2019 , 33, 1545-1555	3.5	12
157	From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1469-1478	5.4	11
156	Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations. <i>Scientific Reports</i> , 2016 , 6, 31983	4.9	11
155	Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile. <i>Molecules</i> , 2017 , 22,	4.8	11
154	A Peptide Derived from the HIV-1 gp120 Coreceptor-Binding Region Promotes Formation of PAP248-286 Amyloid Fibrils to Enhance HIV-1 Infection. <i>PLoS ONE</i> , 2015 , 10, e0144522	3.7	11
153	L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3121-32	5.9	11
152	Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents. <i>European Journal of Medicinal Chemistry</i> , 2010 , 45, 4096-103	6.8	11
151	Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 374, 767-72	3.4	11
150	Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise. <i>Frontiers in Microbiology</i> , 2019 , 10, 29	5.7	10
149	A truncated fragment of Ov-ASP-1 consisting of the core pathogenesis-related-1 (PR-1) domain maintains adjuvant activity as the full-length protein. <i>Vaccine</i> , 2015 , 33, 1974-80	4.1	10
148	Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS. <i>ChemMedChem</i> , 2014 , 9, 1546-55	3.7	10
147	Receptor binding and transmission studies of H5N1 influenza virus in mammals. <i>Emerging Microbes and Infections</i> , 2013 , 2, e85	18.9	10
146	Isolation of Anti-HIV Components from <i>Canarium album</i> Fruits by High-Speed Counter-Current Chromatography. <i>Analytical Letters</i> , 2013 , 46, 1057-1068	2.2	10
145	Genomic signature analysis of the recently emerged highly pathogenic A(H5N8) avian influenza virus: implying an evolutionary trend for bird-to-human transmission. <i>Microbes and Infection</i> , 2017 , 19, 597-604	9.3	10

144	An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation. <i>ChemMedChem</i> , 2011 , 6, 1654-64	3.7	10
143	Heteromeric assembled polypeptidic artificial hydrolases with a six-helical bundle scaffold. <i>ChemBioChem</i> , 2011 , 12, 2647-58	3.8	10
142	HIV-1 gp41 ectodomain enhances <i>Cryptococcus neoformans</i> binding to human brain microvascular endothelial cells via gp41 core-induced membrane activities. <i>Biochemical Journal</i> , 2011 , 438, 457-66	3.8	10
141	Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies. <i>Immunobiology</i> , 2005 , 210, 639-45	3.4	10
140	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.. <i>Cell Research</i> , 2022 ,	24.7	10
139	Fully human single-domain antibodies against SARS-CoV-2		10
138	A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection. <i>Microbes and Infection</i> , 2016 , 18, 148-52	9.3	10
137	Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc. <i>Cellular and Molecular Immunology</i> , 2019 , 16, 757-769	15.4	9
136	Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). <i>Emerging Microbes and Infections</i> , 2015 , 4, e37	18.9	9
135	Advances in the research and development of therapeutic antibodies against the Zika virus. <i>Cellular and Molecular Immunology</i> , 2019 , 16, 96-97	15.4	9
134	Short cyclic peptides derived from the C-terminal sequence of α -antitrypsin exhibit significant anti-HIV-1 activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 2393-5	2.9	9
133	3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 573-6	5.1	9
132	Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, 384-92	3.1	9
131	Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies. <i>AIDS Research and Human Retroviruses</i> , 1991 , 7, 657-62	1.6	9
130	Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. <i>Stem Cell Reports</i> , 2021 , 16, 398-411	8	9
129	design of isopeptide bond-tethered triple-stranded coiled coils with exceptional resistance to unfolding and proteolysis: implication for developing antiviral therapeutics. <i>Chemical Science</i> , 2015 , 6, 6505-6509	9.4	8
128	Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. <i>Virologica Sinica</i> , 2020 , 35, 340-343	6.4	8
127	Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection. <i>Scientific Reports</i> , 2016 , 6, 32161	4.9	8

126	CorMut: an R/Bioconductor package for computing correlated mutations based on selection pressure. <i>Bioinformatics</i> , 2014 , 30, 2073-5	7.2	8
125	Mutation covariation of HIV-1 CRF07_BC reverse transcriptase during antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2521-4	5.1	8
124	High genetic and antigenic similarity between a swine H3N2 influenza A virus and a prior human influenza vaccine virus: a possible immune pressure-driven cross-species transmission. <i>Biochemical and Biophysical Research Communications</i> , 2009 , 385, 402-7	3.4	8
123	Prolongation of corneal xenotransplant survival by T-cell vaccination-induced T-regulatory cells. <i>Xenotransplantation</i> , 2008 , 15, 164-73	2.8	8
122	Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha). <i>Cell Discovery</i> , 2021 , 7, 109	22.3	8
121	Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2. <i>Trends in Immunology</i> , 2020 , 41, 853-854	14.4	8
120	Anti-SARS-CoV-2 IgY Isolated from Egg Yolks of Hens Immunized with Inactivated SARS-CoV-2 for Immunoprophylaxis of COVID-19. <i>Virologica Sinica</i> , 2021 , 36, 1080-1082	6.4	8
119	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. <i>Aids</i> , 2018 , 32, 1749-1761	3.5	8
118	A Degraded Fragment of HIV-1 Gp120 in Rat Hepatocytes Forms Fibrils and Enhances HIV-1 Infection. <i>Biophysical Journal</i> , 2017 , 113, 1425-1439	2.9	7
117	Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action. <i>Viruses</i> , 2019 , 11,	6.2	7
116	A CCR5 antagonist-based HIV entry inhibitor exhibited potent spermicidal activity: Potential application for contraception and prevention of HIV sexual transmission. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 117, 313-320	5.1	7
115	A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41. <i>Amino Acids</i> , 2016 , 48, 2867-2873	3.5	7
114	HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection. <i>Journal of Biological Chemistry</i> , 2011 , 286, 44869-77	5.4	7
113	The ribosomal protein L32-2 (RPL32-2) of <i>S. pombe</i> exhibits a novel extraribosomal function by acting as a potential transcriptional regulator. <i>FEBS Letters</i> , 2006 , 580, 1827-32	3.8	7
112	Resistance to the pore-forming protein of cytotoxic T cells: comparison of target cell membrane rigidity. <i>Molecular Immunology</i> , 1990 , 27, 839-45	4.3	7
111	PEBP1 suppresses HIV transcription and induces latency by inactivating MAPK/NF- κ B signaling. <i>EMBO Reports</i> , 2020 , 21, e49305	6.5	7
110	Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines. <i>Vaccines</i> , 2020 , 8,	5.3	7
109	Intranasal application of polyethyleneimine suppresses influenza virus infection in mice. <i>Emerging Microbes and Infections</i> , 2016 , 5, e41	18.9	7

108	IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. <i>PLoS Pathogens</i> , 2019 , 15, e1008082	7.6	7
107	Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection in vivo. <i>Immunity</i> , 2021 , 54, 2231-2244.e6	32.3	7
106	Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. <i>Journal of Infection</i> , 2017 , 75, 68-71	18.9	6
105	Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection. <i>Viruses</i> , 2015 , 7, 798-819	6.2	6
104	Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 2831-8	4.4	6
103	Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell. <i>ACS Infectious Diseases</i> , 2020 , 6, 882-890	5.5	6
102	In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4. <i>Viruses</i> , 2019 , 11,	6.2	6
101	Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014 , 24, 3719-23	2.9	6
100	Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. <i>Journal of Infection</i> , 2013 , 67, 156-8	18.9	6
99	Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. <i>Scientific Reports</i> , 2017 , 7, 6222	4.9	6
98	Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure. <i>PLoS ONE</i> , 2013 , 8, e66156	3.7	6
97	Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro. <i>European Journal of Medicinal Chemistry</i> , 2011 , 46, 1701-5	6.8	6
96	Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein. <i>Virology</i> , 2006 , 352, 74-85	3.6	6
95	Identification of a D-amino acid decapeptide HIV-1 entry inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 347, 909-15	3.4	6
94	Etiological investigation of acute post-transfusion non-A, non-B hepatitis in China. <i>Journal of Medical Virology</i> , 1993 , 39, 219-23	19.7	6
93	Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.. <i>Cell Research</i> , 2022 ,	24.7	6
92	Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains. <i>PLoS ONE</i> , 2014 , 9, e93804	3.7	6
91	Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally. <i>Journal of Medical Virology</i> , 2016 , 88, 1098-101	19.7	6

90	Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad-spectrum, and safe COVID-19 vaccines and therapeutics. <i>Clinical and Translational Medicine</i> , 2021 , 11, e284	5.7	6
89	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.. <i>Cell</i> , 2022 ,	56.2	6
88	The Underlying Mechanism of 3-Hydroxyphthalic Anhydride-Modified Bovine Beta-Lactoglobulin to Block Human Papillomavirus Entry Into the Host Cell. <i>Frontiers in Microbiology</i> , 2019 , 10, 2188	5.7	5
87	Crystal Structure of Refolding Fusion Core of Lassa Virus GP2 and Design of Lassa Virus Fusion Inhibitors. <i>Frontiers in Microbiology</i> , 2019 , 10, 1829	5.7	5
86	Adenovirus-based vaccines against avian-origin H5N1 influenza viruses. <i>Microbes and Infection</i> , 2015 , 17, 135-41	9.3	5
85	An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	5
84	An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. <i>Chemical Science</i> , 2016 , 7, 2145-2150	9.4	5
83	A Peptide-Based Virus Inactivator Protects Male Mice Against Zika Virus-Induced Damage of Testicular Tissue. <i>Frontiers in Microbiology</i> , 2019 , 10, 2250	5.7	5
82	Highly pathogenic avian influenza A(H5N1) mutants transmissible by air are susceptible to human and animal neutralizing antibodies. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1315-9	7	5
81	Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection. <i>Journal of Visualized Experiments</i> , 2011 ,	1.6	5
80	Four-way ligation for construction of a mammalian cell-based full-length antibody display library. <i>Acta Biochimica Et Biophysica Sinica</i> , 2011 , 43, 232-8	2.8	5
79	Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins. <i>AIDS Research and Human Retroviruses</i> , 1993 , 9, 1195-208	1.6	5
78	Correlation between the prevalence of serum HBV DNA and immunoserologic HBV markers in the subjects with or without hepatitis. <i>Immunological Investigations</i> , 1992 , 21, 275-81	2.9	5
77	The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entry. <i>PLoS ONE</i> , 2012 , 7, e44874	3.7	5
76	Simultaneous expression of displayed and secreted antibodies for antibody screen. <i>PLoS ONE</i> , 2013 , 8, e80005	3.7	5
75	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 378	21	5
74	25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
73	Topical Application of a Vitamin A Derivative and Its Combination With Non-ablative Fractional Laser Potentiates Cutaneous Influenza Vaccination. <i>Frontiers in Microbiology</i> , 2018 , 9, 2570	5.7	5

72	Pathogenic Streptococcus strains employ novel escape strategy to inhibit bacteriostatic effect mediated by mammalian peptidoglycan recognition protein. <i>Cellular Microbiology</i> , 2017 , 19, e12724	3.9	4
71	Genome-wide analysis of an avirulent strain that induces protective immunity against challenge with virulent Streptococcus suis serotype 2. <i>BMC Microbiology</i> , 2017 , 17, 67	4.5	4
70	Design and Biological Evaluation of -Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 gp41 Hexameric Coiled-Coil Fusion Complex. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 8773-8783	8.3	4
69	A stereo configuration-activity study of 3-iodo-4-(2-methylcyclohexyloxy)-6-phenethylpyridin-2(2H)-ones as potency inhibitors of HIV-1 variants. <i>Organic and Biomolecular Chemistry</i> , 2016 , 14, 1413-20	3.9	4
68	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2019 , 93,	6.6	4
67	FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model. <i>Microbes and Infection</i> , 2014 , 16, 409-18	9.3	4
66	Receptor binding domain based HIV vaccines. <i>BioMed Research International</i> , 2015 , 2015, 594109	3	4
65	3-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 1455-64	1.6	4
64	Biosecurity and biosafety in research on emerging pathogens. <i>Emerging Microbes and Infections</i> , 2012 , 1, e44	18.9	4
63	Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 376, 60-4	3.4	4
62	Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion		4
61	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. <i>Acta Pharmaceutica Sinica B</i> , 2021 ,	15.5	4
60	Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.. <i>Cell Discovery</i> , 2022 , 8, 36	22.3	4
59	A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor. <i>Viruses</i> , 2019 , 11,	6.2	3
58	Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection. <i>Lancet, The</i> , 2015 , 386, S44	4.0	3
57	dl-Mandelic acid exhibits high sperm-immobilizing activity and low vaginal irritation: A potential non-surfactant spermicide for contraception. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 126, 110104	7.5	3
56	3-Hydroxyphthalic Anhydride- Modified Rabbit Anti-PAP IgG as a Potential Bifunctional HIV-1 Entry Inhibitor. <i>Frontiers in Microbiology</i> , 2018 , 9, 1330	5.7	3
55	Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains. <i>Molecules</i> , 2018 , 23,	4.8	3

54	F(ab') ₂ fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket. <i>Microbes and Infection</i> , 2013 , 15, 887-94	9.3	3
53	Potential strategies and biosafety protocols used for dual-use research on highly pathogenic influenza viruses. <i>Reviews in Medical Virology</i> , 2012 , 22, 412-9	11.7	3
52	Developing pan-Ecoronavirus vaccines against emerging SARS-CoV-2 variants of concern.. <i>Trends in Immunology</i> , 2022 ,	14.4	3
51	Up-regulation of human cervical cancer proto-oncogene contributes to hepatitis B virus-induced malignant transformation of hepatocyte by down-regulating E-cadherin. <i>Oncotarget</i> , 2015 , 6, 29196-208 ³ ·3		3
50	Dynamics of HIV-1 quasispecies diversity of participants on long-term antiretroviral therapy based on intrahost single-nucleotide variations. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 306-314 ¹⁰ ·5		3
49	Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection. <i>Molecules</i> , 2021 , 26,	4.8	3
48	A natural "GA" insertion mutation in the sequence encoding the 3'UTR of CXCL12/SDF-1β Identification, characterization, and functional impact on mRNA splicing. <i>Gene</i> , 2019 , 681, 36-44	3.8	3
47	Ring vaccination of COVID-19 vaccines in medium- and high-risk areas of countries with low incidence of SARS-CoV-2 infection. <i>Clinical and Translational Medicine</i> , 2021 , 11, e331	5.7	3
46	Current Progress in the Development of Zika Virus Vaccines. <i>Vaccines</i> , 2021 , 9,	5.3	3
45	Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1. <i>Frontiers in Pharmacology</i> , 2020 , 11, 613361	5.6	3
44	Enhancement of endocytic uptake of HIV-1 virions into CD4-negative epithelial cells by HIV-1 gp41 via its interaction with POB1. <i>Cellular and Molecular Immunology</i> , 2017 , 14, 568-571	15.4	2
43	HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen. <i>Emerging Microbes and Infections</i> , 2017 , 6, e102	18.9	2
42	HIV type 1 B'/C recombinant (CRF07_BC) in virologic noncontrollers elicits neutralizing antibodies against heterologous but not autologous viruses. <i>AIDS Research and Human Retroviruses</i> , 2010 , 26, 237-9 ¹ ·6		2
41	Drug-resistant viruses may repair impaired fitness by mutations outside the drug target site. <i>Future Microbiology</i> , 2009 , 4, 507-9	2.9	2
40	What can academia learn from XMRV studies?. <i>Nature Reviews Urology</i> , 2012 , 9, 174; author reply 174	5.5	2
39	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody		2
38	Engineered Trimeric ACE2 Binds and Locks Three-up Spike Protein to Potently Inhibit SARS-CoVs and Mutants		2
37	A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses. <i>Cell and Bioscience</i> , 2021 , 11, 128	9.8	2

36	A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 11460-11471	8.3	2
35	Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 318	21	2
34	An ultrapotent pan- β coronavirus lineage B (β CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2021 , 1	7.2	2
33	Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2021 , 10, 439-441	18.9	2
32	A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant.. <i>Cell Research</i> , 2022 ,	24.7	2
31	The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4882-8	5.9	1
30	No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E5115	11.5	1
29	Influenza virus glycoprotein-reactive human monoclonal antibodies. <i>Microbes and Infection</i> , 2020 , 22, 263-271	9.3	1
28	Reply to 'Trace N-glycans including sulphated species may originate from various plasma glycoproteins and not necessarily IgG'. <i>Nature Communications</i> , 2018 , 9, 2915	17.4	1
27	Semen-mediated Enhancement of HIV Infection Markedly Impairs the Antiviral Efficacy of Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A183-A183	1.6	1
26	Phylogenetic and biological analysis of a laboratory-generated gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV). <i>Virus Genes</i> , 2012 , 45, 218-24	2.3	1
25	Pathogenesis and treatment of human immunodeficiency virus-associated cytomegalovirus retinitis. <i>Future Virology</i> , 2011 , 6, 503-520	2.4	1
24	Fab crystallization and preliminary X-ray analysis of NC-1, an anti-HIV-1 antibody that recognizes the six-helix bundle core of gp41. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2010 , 66, 854-7		1
23	A complex aetiological connotation of acute non-A, non-B hepatitis in China. <i>Journal of Hepatology</i> , 1994 , 21, 916	13.4	1
22	Anti-idiotypic antibodies derived against C8, C9 and perforin bind homologous restriction factor. <i>Journal of Immunological Methods</i> , 1990 , 128, 133-42	2.5	1
21	An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies		1
20	Immunoengineered adjuvants for universal vaccines against respiratory viruses. <i>Fundamental Research</i> , 2021 , 1, 189-192		1
19	Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human β Coronavirus Infection. <i>Journal of Medicinal Chemistry</i> , 2021 ,	8.3	1

18	Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection. <i>Microbes and Infection</i> , 2021 , 23, 104840	9.3	1
17	Double insult: flu bug enhances SARS-CoV-2 infectivity. <i>Cell Research</i> , 2021 , 31, 491-492	24.7	1
16	A safe and effective mucosal RSV vaccine in mice consisting of RSV phosphoprotein and flagellin variant. <i>Cell Reports</i> , 2021 , 36, 109401	10.6	1
15	FKBP3 Induces Human Immunodeficiency Virus Type 1 Latency by Recruiting Histone Deacetylase 1/2 to the Viral Long Terminal Repeat. <i>MBio</i> , 2021 , 12, e0079521	7.8	1
14	China needs safe and effective microbicides for preventing sexual transmission of HIV. <i>Lancet Infectious Diseases</i> , 2006 , 6, 681-2	25.5	0
13	A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells.. <i>MBio</i> , 2022 , e0338421	7.8	0
12	Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.. <i>Current Opinion in Virology</i> , 2021 , 53, 101199	7.5	0
11	Disease of influenza virus and SARS-CoV-2 coinfection: Flurona or FluCovid?. <i>Journal of Medical Virology</i> , 2022 ,	19.7	0
10	Normal human sera contain heat-sensitive factor(s) to enhance H7N9 influenza virus infection. <i>Journal of Infection</i> , 2016 , 72, 123-5	18.9	
9	An artificial peptide-based HIV-1 fusion inhibitor containing M-T hook structure exhibiting improved antiviral potency and drug resistance profile. <i>Future Virology</i> , 2015 , 10, 961-969	2.4	
8	Development of small-molecule inhibitors against hantaviruses. <i>Microbes and Infection</i> , 2020 , 22, 272-273	3.3	
7	The interaction between the membrane-proximal external region and the N-trimer region of HIV-1 gp41: Involvement in viral fusion. <i>Science Bulletin</i> , 2009 , 54, 1707-1712	10.6	
6	Biorisk management in studies of highly pathogenic H5N1 viruses. <i>Future Virology</i> , 2012 , 7, 637-639	2.4	
5	Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time.. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022 , 12, 862754	5.9	
4	Design of artificial helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors.. <i>European Journal of Medicinal Chemistry</i> , 2022 , 236, 114336	6.8	
3	Small-Molecule HIV Entry Inhibitors Targeting gp120 and gp41.. <i>Advances in Experimental Medicine and Biology</i> , 2022 , 1366, 27-43	3.6	
2	Virus Entry Inhibitors: Past, Present, and Future.. <i>Advances in Experimental Medicine and Biology</i> , 2022 , 1366, 1-13	3.6	
1	Peptide-Based HIV Entry Inhibitors.. <i>Advances in Experimental Medicine and Biology</i> , 2022 , 1366, 15-26	3.6	

